UA137832U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination, radiography, in addition in the patient's serum determine the polymorphism of the nitric oxide synthase gene (eNOS T786C), the content of thrombomodulin, folic acid, homocysteine, osteocalcin, protein-6, rea-6 ) and with a homozygous carrier of 786-CC, levels of thrombomodulin> 5 ng / ml, folic acid <6 ng / ml, homocysteine> 20 μmol / l, osteocalcin <21 ng / ml, PSA> 6 mg / l, IL-6> 10 ng / l predict the development of osteoarthritis.

Description

The proposed useful model The method of predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (Okorokov

A.N. Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the inability to predict the dynamics of the process in the early subclinical stages, the inability to prevent its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, the polymorphism of the nitric oxide synthase gene (emo5 1786C), the content of thrombomodulin, folic acid, homocysteine, osteocalcin, C-reactive protein (CRP), interleukin 6 (IL) is determined in the patient's blood serum -6) and with homozygous carrier 786-SS, levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, homocysteine 220 μmol/l, osteocalcin "21 ng/ml, SRP 26 mg/l,

IL-6 210 ng/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, x-rays are taken, the eMmo5 gene polymorphism T786C is determined, the content of thrombomodulin, folic acid, homocysteine, osteocalcin, SRP, IL-6 is determined by the immunoenzymatic method. With homozygous carrier 786-SS and levels of thrombomodulin "5 ng/ml, folic acid "b ng/ml, homocysteine "20 μmol/l, osteocalcin "21 ng/ml, SRP 26 mg/l, IL-6 210 ng/l predict the development of osteoarthritis.

A specific example of using the method

Patient V., 60 years old, was hospitalized in the clinic due to pain syndrome in the left knee joint. Examined, X-ray taken. No signs of osteoarthritis were found. The eMmo5 T786C gene polymorphism and thrombomodulin, folic acid, homocysteine, osteocalcin, SRP, IL-6 content were determined in the serum. A homozygous carrier of 786-SS was established, the levels of thrombomodulin 12 ng/ml, folic acid 2.9 ng/ml, homocysteine - 30 μmol/l, osteocalcin - 13 ng/ml, SRP -19 mg/l, IL-6 28 ng/ l. Diagnosed

From the development of osteoarthritis. After 13 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that the polymorphism of the nitric oxide synthase gene (EMO T786C), the content of thrombomodulin, folic acid, homocysteine, osteocalcin, C-reactive protein (CRP) is determined in the patient's blood serum. , interleukin b (IL-6) and with homozygous carrier 786-SS, levels of thrombomodulin 25 ng/ml, folic acid "6 ng/ml, homocysteine 220 μmol/l, osteocalcin "21 ng/ml, SRP "b mg/l , IL-b6 »10 ng/l predict the development of osteoarthritis.